All In Biotech

Investigational drug · Phase 3

177Lu-PSMA-617

Also called: Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetan

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC).

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

84

Any phase or sponsor naming "177Lu-PSMA-617"

First trial start

2021

Jun 9, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "177Lu-PSMA-617", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostatic Neoplasms
  • Prostatic Neoplasm
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "177Lu-PSMA-617" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 203 on PubMed

Also in development for Prostatic Neoplasms

  • OpevesostatMK-5684, ODM-208Phase 37 trials

    Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • 64Cu-SAR-bisPSMAPhase 33 trials

    Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms

  • ARDTPhase 32 trials

    Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

  • JNJ-101556143Phase 32 trials

    Johnson & Johnson (Janssen) · Prostatic Neoplasms

  • GV20-0251Phase 23 trials

    GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum

  • QLH12016Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer

  • DM002Phase 21 trial

    Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.